FDA determines PEPCID RPD famotidine tablets not withdrawn for safety or effectiveness
The agency decided that the 20 mg and 40 mg orally disintegrating tablets were not removed from sale. This determination will allow FDA to approve abbreviated new drug applications for these products if all other legal and regulatory requirements are met.
Primary source
Federal Register notice, October 27, 2026
Determination That PEPCID RPD (Famotidine) Orally Disintegrating Tablets, 20 Milligrams and 40 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Machine-summarized from the source above; not independently reported. How we use automation